Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026

Same author

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

JAMA oncology·2026

Same author

Phase 1 Study of [<sup>177</sup>Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Same author

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.

Hematology/oncology clinics of North America·2025

Same author

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1<sup>T315I</sup> treated with at least 2 prior TKIs: Phase 1 final results.

Leukemia·2025

Search research articles

Related Experiment Video

Updated: May 10, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

PDGFRA Antibody for Soft Tissue Sarcoma.

Lillian R Klug¹, Michael C Heinrich¹

¹Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, OR 97239, USA.

|February 11, 2017

Summary

This summary is machine-generated.

Lartruvo (olaratumab) is a PDGFRA-targeting antibody that improved survival when added to doxorubicin chemotherapy in a Phase II study. This antibody inhibits PDGFRA kinase activity, showing promise in preclinical cancer models.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Related Experiment Videos

Last Updated: May 10, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Area of Science:

Oncology
Immunotherapy
Molecular Biology

Background:

Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) is implicated in tumor growth.
Targeting PDGFRA presents a potential therapeutic strategy in oncology.

Purpose of the Study:

To evaluate the efficacy and safety of olaratumab, a monoclonal antibody targeting PDGFRA.
To assess the benefit of adding olaratumab to doxorubicin chemotherapy in patients with advanced soft tissue sarcoma.

Main Methods:

A randomized Phase II clinical study was conducted.
Patients received either doxorubicin alone or doxorubicin plus olaratumab.
Overall survival was a primary endpoint.

Main Results:

Adding olaratumab to doxorubicin significantly improved overall survival compared to doxorubicin alone.
Olaratumab demonstrated a manageable safety profile when combined with doxorubicin.
Preclinical studies showed inhibition of PDGFRA-dependent tumor growth.

Conclusions:

Olaratumab in combination with doxorubicin offers a survival benefit for patients.
Olaratumab represents a novel therapeutic approach targeting the PDGFRA pathway in cancer treatment.
FDA approval was granted based on these findings.